<DOC>
	<DOC>NCT01175239</DOC>
	<brief_summary>X-linked severe combined immunodeficiency (SCID-X1) is an inherited disorder that results in failure of development of the immune system in boys. This trial aims to treat SCID-X1 patients using gene therapy to replace the defective gene.</brief_summary>
	<brief_title>Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>X-Linked Combined Immunodeficiency Diseases</mesh_term>
	<criteria>1. No HLA identical (A,B,C,DR,DQ) family donor and no HLA identical unrelated donor available within 3 months of diagnosis or patients whose underlying clinical problems and prognosis would be significantly compromised by chemotherapy conditioning (including persisting pneumonitis, protracted diarrhoea requiring parental nutrition, ongoing visceral viral infection (herpes viruses, HSV,VZV,CMV, EBV or adenovirus), systemic BCG infection, virusinduced lymphoproliferation. 2. Diagnosis of classical SCIDX1 based on immunophenotype (absent, or reduced numbers of nonfunctional T lymphocytes) and confirmed by DNA sequencing 3. Parental/guardian voluntary consent 4. Boys between the ages of 0 and 16</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>X-linked severe combined immunodeficiency, gene therapy</keyword>
	<keyword>Patients will be enrolled following diagnosis and referral to Great Ormond Street Immunology Service.</keyword>
</DOC>